PubMed · 2025737
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
1991-04-13. Confidence intervals and sample sizes.. https://pubmed.ncbi.nlm.nih.gov/2025737/
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
Expression of mdm-2 mRNA was measured in 90 ovarian-cancer tissue specimens using the S1 nuclease assay, to investigate a possible association between MDM2 expression and prognosis. mdm-2 mRNA expression was an independent prognostic factor for patients with primary ovarian cancer, FIGO (International Federation of Gynecology and Obstetrics) stages III and IV (n = 57), who all received chemotherapy with carboplatin or cisplatin and cyclophosphamide. Median survival time for patients (FIGO stages III and IV) with no detectable expression of mdm-2 mRNA (n = 14) was 171 days, as compared with 839 days for patients (n = 43) with detectable mdm-2 mRNA (p = 0.0194; log-rank test). However, no association between mdm-2 mRNA expression and survival was observed for patients with FIGO stages I and II who did not receive chemotherapy. mdm-2 expression was not associated with FIGO stage, residual disease, histologic grade and type. Our results suggest that mdm-2, which is known to disrupt p53 function, sensitizes ovarian-cancer cells to cisplatin/cyclophosphamide, possibly by inhibition of p53-mediated G1 cell-cycle arrest and p53-stimulated nucleotide-excision repair.
In analysing maternal-child HIV transmission from Medicaid claims data, we must deal with follow-up that is sometimes so short that we cannot claim that an apparently uninfected infant is actually uninfected as opposed to not yet exhibiting HIV-associated symptoms. To overcome this, we have been using analyses of 'time-to-diagnosis' of HIV infection to estimate transmission rates and predictors of transmission. Such analyses mix the event of transmission with that of our ability to diagnose HIV infection from coded claims data. We would like to separate these two pieces. Also, due to incomplete follow-up, Kaplan-Meier analyses will underestimate transmission rates. In econometrics and biostatistics there are two-part (mixture) models that can serve the goal of separating transmission from the process of diagnosing HIV infection in the newborn. Farewell describes a model that combines a logistic regression for the yes/no event (in our case, HIV transmission) and a Weibull regression model for the survival analysis portion (in our case, time-to-diagnosis). We use this approach to fit models that have potentially separate covariates for transmission and for time-to-diagnosis. The results allow us to identify predictors of transmission and estimate transmission rates with reduced concern for adequacy of follow-up.
When data are dichotomous, this paper notes the utility of inverse sampling in establishing equivalence with respect to the risk ratio. This paper develops an exact equivalence test that accounts for the risk ratio under inverse sampling and further discusses the relationship between the exact equivalence test and the exact conditional confidence limits. Also included are an exact and two asymptotic procedures for calculation of the minimum required number of index subjects for a desired power 1--beta at a given alpha-level. Finally, this paper provides a table that summarizes the minimum required number of index subjects for powers equal to 0.90 and 0.80 in application of the proposed exact equivalence test at 0.05-level in a variety of situations.